Helix BioPharma Corp. reported a net loss and total comprehensive loss of $3,354,000, or $0.04 per common share, for the fiscal year ended July 31, 2026, an improvement of roughly 36% from the $5,205,000 loss, or $0.09 per share, recorded a year earlier. The reduced deficit matters because it reflects a deliberate shrinking of the company's cost base while it tries to fund its next clinical step, but it also exposes how little room the clinical-stage oncology developer has left to maneuver.
Research and development expenses fell 54% to $1,620,000 from $3,558,000, a decrease the company attributed largely to the wind-down of earlier clinical activities, including the LDOS006 study in metastatic pancreatic adenocarcinoma, and to the deferral of work with external service providers for the next phase of L-DOS47 and other pipeline programs pending successful fundraising. Operating, general and administration expenses rose 10% to $2,019,000, driven by stock-based compensation tied to 1,297,000 options granted in May 2026 and the full-year impact of officers appointed in 2025. The detailed breakdown is set out in Table 1 and Table 2.
The balance sheet is the more urgent story. As at July 31, 2026, Helix had cash reserves of $804,000, a working capital deficiency of $4,181,000, shareholders' equity of $14,208,000 and an accumulated deficit of $219,230,000. Management stated plainly that the cash on hand is insufficient to meet anticipated working capital and capital expenditure requirements over the next twelve months or to complete current research and development initiatives. The company's financing strategy now contemplates bridge financing to support near-term objectives and prepare for a larger raise intended to fund the planned Phase Ib/randomized Phase II study of L-DOS47 in combination with pembrolizumab as first-line therapy in non-small cell lung cancer. That trial is the central asset in the pipeline, so the financing gap is effectively a gating item for the entire investment case.
Helix has been active on the corporate and scientific fronts. It appointed Markus Loeffler as Chief Medical Officer in August 2026, added Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations in June 2026, and reconstituted its board in September 2026 under Chair Karen Krumeich. In February 2026 it presented preclinical data on its CEACAM6-directed antibody-drug conjugate program at the World ADC London conference and extended its option agreement with metaShape Pharma AG for LEUMUNA through December 2028. It also received written FDA feedback on the LDOS007 study design and elected to proceed directly to preparing a Clinical Trial Application.
Financing history illustrates the risk. A $33,370,000 subscription agreement signed in December 2025 did not close after the subscriber declared bankruptcy, and in May 2026 the company issued $3,673,000 of unsecured convertible debentures bearing 25% annual interest and maturing July 27, 2027, convertible at $1.42 per share. The shares closed at $0.92 on October 8, 2026, well below that conversion price. Full statements are available on SEDAR+ and the company's website at www.helixbiopharma.com, with summary figures in Table 3.
